Marco Londei sold $1.85M worth of shares in AnaptysBio, Inc. in December 2018

Jan 08, 2019
Insider Transactions
Background Information
Marco Londei
Former Head-Therapeutic Area Immunosciences at Bristol-Myers Squibb Company
Career
Bristol-Myers Squibb Company
AnaptysBio, Inc.
Novartis Institute For Functional Genomics, Inc.
Education
Alma Mater Studiorum - Università di Bologna
In The News
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
Jun 05, 2019 - GlobeNewswire
Marco Londei sold $1.2M worth of shares in AnaptysBio, Inc. in January 2019
Feb 08, 2019 - RelSci
Marco Londei sold $1.85M worth of shares in AnaptysBio, Inc. in December 2018
Jan 08, 2019 - RelSci
AnaptysBio, Inc.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
In The News
Learning From Stock Market Losers
Jan 14, 2021 - Nasdaq
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 07, 2021 - GlobeNewswire
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
Nov 13, 2020 - GlobeNewswire
Check out News Home to stay on top of the people and organizations you care most about.
Mentioned Entities
AnaptysBio, Inc.
Marco Londei
Check out News Home to stay on top of the people and organizations you care most about.
Mentioned Entities
AnaptysBio, Inc.
Marco Londei